Engineered immune cells aim to tame autoimmune diseases
NCT ID NCT07507201
First seen Apr 10, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that cause autoimmune diseases like lupus and kidney disease. The treatment involves a one-time infusion after a short chemotherapy-like prep. The main goals are to check safety and see if the disease improves within 90 days. Up to 15 people with hard-to-treat autoimmune conditions will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.